Preparation for and use of heteroaryl derivatives

By developing heteroaryl derivatives, the problem of the lack of effective LRRK2 and EGFR kinase inhibitors in existing technologies has been solved, enabling effective treatment and prevention of related diseases, especially central nervous system diseases, cancer, and immune diseases.

WO2024240118A1PCT designated stage expired Publication Date: 2024-11-28DM INTELLIGENCE LTD +1
View PDF 7 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2024/094263
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-23
Filing Date
2024-05-20
Publication Date
2024-11-28

AI Technical Summary

Technical Problem

The lack of effective and selective LRRK2 kinase or abnormal LRRK2 mutant kinase inhibitors and EGFR mutant kinase inhibitors in the current technology for the treatment of neurodegenerative diseases and cancers associated with LRRK2 or EGFR results in limited treatment options.

Method used

A heteroaryl derivative has been developed with significant inhibitory activity against LRRK2 kinase or abnormal LRRK2 mutant kinase and EGFR mutant kinase, for use in the preparation of related drugs, including LRRK2 kinase inhibitors, EGFR mutant kinase inhibitors or dual inhibitors, for application in the preparation of drugs for the prevention and treatment of central nervous system diseases, cancer and immune diseases.

Benefits of technology

This heteroaryl derivative exhibits significant enzyme-inhibiting activity, effectively inhibiting LRRK2 and EGFR kinases, providing better treatment options for the treatment and prevention of related diseases, including Alzheimer's disease, cancer, and immune disorders.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2024094263_28112024_PF_FP_ABST
    Figure CN2024094263_28112024_PF_FP_ABST
Patent Text Reader

Abstract

Preparation for and the use of heteroaryl derivatives (I). The heteroaryl derivatives can be used for treating or preventing diseases related to inhibiting activities of one or more kinases. The present invention relates to the field of medicines. Further provided is the use of said heteroaryl derivatives and stereoisomers, prodrugs, solvates, polymorphs, hydrates, deuterated analogues, prodrugs, pharmaceutically acceptable salts or excipients thereof as active ingredients in preparing pharmaceutical compositions for preventing or treating central nervous system diseases, cancers and immunological diseases.
Need to check novelty before this filing date? Find Prior Art

Description

Preparation and use of heteroaryl derivatives Technical Field

[0001] The present application relates to the technical field of organic compounds, and in particular to the preparation and use of heteroaryl derivatives. Background Art

[0002] LRRK2 (leucine-rich repeat kinase-2) protein belongs to the leucine-rich repeat kinase family and consists of a 2527 amino acid sequence with high interspecies similarity. The LRRK2 protein is characterized by showing GTPase and serine-threonine kinase activity in a single protein. LRRK2 protein expression has been observed in a variety of organs and tissues including the brain, and it is present in the cytoplasm or cell membrane and mitochondrial outer membrane at the cellular level. In addition, the LRRK2 protein has five functionally important domains, and it is inferred that it regulates cellular functions through protein interactions and enzymatic actions as well as through the autoregulatory effect of autophosphorylation. In particular, it is known that the chaperone mechanism, cytoskeletal arrangement, protein translation mechanism, synaptic vesicle endocytosis, mitogen-activated protein kinase-type cascade and ubiquitin / autophagy protein degradation pathway are regulated by the LRRK2 protein.

[0003] It is reported that LRRK2 protein is associated with the progression of mild cognitive impairment associated with Alzheimer's disease, levodopa-induced movement disorders, and central nervous system diseases related to neural precursor differentiation. In addition, it is reported that the S2019S mutation of the LRRK2 protein increases the incidence of non-skin cancers, such as acute myeloid leukemia, kidney cancer, breast cancer, lung cancer, prostate cancer, etc. Specifically, the G2019S mutation of the LRRK2 protein increases the catalytic activity of the LRRK2 kinase domain. In addition, it is reported that LRRK2 protein is also associated with amyotrophic lateral sclerosis, rheumatoid arthritis, and ankylosing spondylitis. High expression of LRRK2 is highly correlated with advanced clinical features and poor survival rates in ovarian cancer patients. The inhibition or depletion of LRRK2 increases the sensitivity of ovarian cancer cells to breast cancer drugs and enhances drug efficacy.

[0004] EGFR is a receptor for epidermal growth factor (EGF) cell proliferation and signal transduction. EGFR belongs to the ErbB receptor family, which includes EGFR (ErbB-1), HER2 / c-neu (ErbB-2), HER3 (ErbB-3), and HER4 (ErbB-4). EGFR is also known as HER1 and ErbB1. EGFR is widely distributed on the surface of mammalian epithelial cells, fibroblasts, glial cells, keratinocytes, and other cells. The EGFR signaling pathway plays an important role in physiological processes such as cell growth, proliferation, and differentiation. EGFR is divided into three regions: the extracellular ligand binding region, the transmembrane region, and the intracellular kinase region. When EGFR is bound by the corresponding ligand, it is induced to form homo- or heterodimers, thereby activating the intracellular tyrosine kinase pathway and causing its own phosphorylation, thereby guiding downstream phosphorylation, including the MAPK, Akt, and JNK pathways, and inducing cell proliferation. EGFR mutant kinase inhibitors block the binding of endogenous ATP to the intracellular kinase region, thereby inhibiting receptor phosphorylation and the activation of its downstream signal transduction molecules, thereby blocking the proliferation of tumor cells.

[0005] Although much research has been done on inhibitors of LRRK2 kinase or abnormal LRRK2 mutant kinase and EGFR mutant kinase, there are currently limited treatment options. There is still a need to develop effective and selective inhibitors of LRRK2 kinase or abnormal LRRK2 mutant kinase and EGFR mutant kinase for the treatment and / or prevention of neurodegenerative diseases or other diseases associated with LRRK2 or / and EGFR.

[0006] Summary of the Invention

[0007] The present application provides a heteroaryl derivative and provides applications of the compound.

[0008] The technical solutions of the present invention are as follows:

[0009] 1. Heteroaryl derivatives

[0010] A heteroaryl derivative, or a pharmaceutically acceptable salt, ester or prodrug thereof, has the following general structural formula I:

[0011] in:

[0012] X and Y are independently selected from halogen or hydrogen, or together with the nitrogen-containing six-membered ring to which they are connected, form a nitrogen-containing five-membered ring;

[0013] Preferably, Y is selected from Cl, X is selected from H, or the nitrogen-containing six-membered ring to which they are connected together forms

[0014] R1 is a 5-6 membered aryl group or a heteroaryl group containing N and S, and the aromatic ring and heteroaryl group are substituted by 0-2 substituents, and the substituents are C1-3 alkyl groups or alkyl groups substituted by cyano groups; or two substituents can be connected to form a ring, and the ring is a 5-7 membered cycloalkyl group, a lactamcycloalkyl group or a heterocycloalkyl group or heteroaryl group containing N and O, and the heterocycloalkyl group or heteroaryl group is substituted by 0-3 substituents, and the substituents are C1-3 alkyl groups, keto groups, trifluoroacetyl groups, hydroxyacetyl groups, alkylamino groups, and heterocycloalkanoyl groups.

[0015] Preferably, R1 is One of them.

[0016] Preferably, the compound of formula I is one of the following:

[0017] Preparation of (2-((5-chloro-2-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide;

[0018] (2-(2-(1-methyl-1H-pyrazol-4-yl)amino)-7H-purin-6-yl)amino)phenyl)dimethylphosphine oxide;

[0019] (2-(2-(1-methyl-1H-pyrazol-3-yl)amino)-7H-purin-6-yl)amino)phenyl)dimethylphosphine oxide;

[0020] (2-(2-((1H-indazol-6-yl)amino)-7H-purin-6-amino)phenyl)dimethylphosphine oxide;

[0021] (2-((5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)amino)-7H-purin-6-yl)amino)phenyl)dimethylphosphine oxide;

[0022] 1-(2-((6-((2-(dimethylphosphoryl)phenyl)amino)-7H-purin-2-yl)amino)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)-2,2,2-trifluoroethanone

[0023] 1-(2-((6-((2-(dimethylphosphoryl)phenyl)amino)-7H-purin-2-yl)amino)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)-2-hydroxyethan-1-one

[0024] (2-((2-((5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)amino)-7H-purin-6-yl)amino)phenyl)dimethylphosphine oxide;

[0025] 6-((6-((2-(dimethylphosphoryl)phenyl)amino)-7H-purin-2-yl)amino)-3,4-dihydroquinolin-2(1H)-one;

[0026] (2-((2-(1,2,3,4-tetrahydroquinolin-6-yl)amino)-7H-purin-6-yl)amino)phenyl)dimethylphosphine oxide;

[0027] 7-((6-((2-(dimethylphosphoryl)phenyl)amino)-7H-purin-2-yl)amino)-3,4-dihydroquinolin-2(1H)-one;

[0028] (2-((2-(1,2,3,4-tetrahydroquinolin-7-yl)amino)-7H-purin-6-yl)amino)phenyl)dimethylphosphine oxide;

[0029] 2-(4-((6-((2-(dimethylphosphoryl)phenyl)amino)-7H-purin-2-yl)amino)-3-methyl-1H-pyrazol-1-yl)-2-methylpropionitrile;

[0030] (2-((6-(((2,3-Dihydrobenzo[b][1,4]dioxin-6-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide;

[0031] (2-((6-(((5-methyl-4,5,6,7-tetrahydrothiazol[5,4-c]pyridin-2-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide;

[0032] (2-((6-((6-propylamino)-4,5,6,7-tetrahydrobenzo[d]thiazol-2-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide;

[0033] 1-(2-((4-((2-(dimethylphosphoryl)phenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-6-yl)amino)-7,8-dihydro-1,6-naphthyridin-6(5H)yl)-2,2,2-trifluoroethanone;

[0034] (2-((6-((5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide;

[0035] 1-(3-((4-((2-(dimethylphosphoryl)phenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-6-yl)amino)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)-2-hydroxyethan-1-one;

[0036] (2-((2-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide;

[0037] (2-((2-((5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)amino)-7Hpyrrolo[2,3-d]pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide;

[0038] 1-(2-((4-((2-(dimethylphosphoryl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)-2-hydroxyethan-1-one;

[0039] 1-(2-((4-((2-(dimethylphosphoryl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)-2-2,2,2-trifluoroethanone;

[0040] (2-((5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide;

[0041] 2-(4-((4-)((2-(dimethylphosphoryl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methyl-1H-pyrazol-1-yl)-2-methylpropionitrile;

[0042] 6-((4-((2-(dimethylphosphoryl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3,4-dihydroquinolin-2(1H)-one;

[0043] (2-(((1,2,3,4-tetrahydroquinolin-6-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)aminophenyl)dimethylphosphine oxide;

[0044] 7-((4-((2-(dimethylphosphoryl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3,4-dihydroquinolin-2(1H)-one;

[0045] (2-(((1,2,3,4-tetrahydroquinolin-7-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)aminophenyl)dimethylphosphine oxide;

[0046] 1-(2-((4-((2-(dimethylphosphoryl)phenyl)amino)-5H-pyrrolo[3,2-d]pyrimidin-2-yl)amino)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)-2-hydroxyethan-1-one;

[0047] 2-(2-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)amino)-5H-pyrrolo[3,2-d]pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide;

[0048] (2-((5-chloro-2-((6-(propylamino)-4,5,6,7-tetrahydrobenzothiazol-2-yl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide;

[0049] 1-(2-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)-2,2,2-trifluoroethanone;

[0050] (2-(5-chloro-2-((5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)amino)pyrimidin-4-yl)amine)phenyldimethylphosphine oxide;

[0051] (2-((5-chloro-2-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide;

[0052] 1-(2-(5-chloro-4-(2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)-2-hydroxyethan-1-one;

[0053] (2-((5-chloro-2-((6-methyl-5,6,7,8-tetrahydro-4H-thiazolo[4,5-d]azepin-2-yl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide;

[0054] 2-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-7,8-dihydro-4H-thiazolo[4,5-d]azepin-6(5H)-yl)(tetrahydro-2H-pyran-4-yl)methanone;

[0055] 2-(4-(5-chloro-4-(2-dimethylphosphonophenyl)aminopyrimidin-2-ylamino)-3-methylpyrazole-2-methylpropionitrile.

[0056] 2. Application of Heteroaryl Derivatives

[0057] The heteroaryl derivatives of the general formula I of the present invention show significant enzyme inhibitory activity in LRRK2 kinase or abnormal LRRK2 mutant kinase and / or EGFR mutant kinase inhibitory activity experiments;

[0058] Therefore, the present application provides the use of heteroaryl derivatives in the preparation of drugs related to the inhibition of LRRK2 kinase or abnormal LRRK2 mutant kinase and / or EGFR mutant kinase.

[0059] An inhibitor of LRRK2 kinase or abnormal LRRK2 mutant kinase comprises the heteroaryl derivative of the present invention or its enantiomer, diastereomer, tautomer, solvate, polymorph, hydrate, deuterated analog, prodrug, pharmaceutically acceptable salt or excipient.

[0060] An EGFR mutant kinase inhibitor comprises the heteroaryl derivative of the present invention or its enantiomer, diastereomer, tautomer, solvate, polymorph, hydrate, deuterated analog, prodrug, pharmaceutically acceptable salt or excipient.

[0061] A dual inhibitor of LRRK2 kinase or abnormal LRRK2 mutant kinase and EGFR mutant kinase comprises the heteroaryl derivative of the present invention or its enantiomer, diastereomer, tautomer, solvate, polymorph, hydrate, deuterated analog, prodrug, pharmaceutically acceptable salt or excipient.

[0062] Use of the heteroaryl derivatives of general formula I described herein, or pharmaceutically acceptable salts or excipients thereof, or pharmaceutical compositions, or dual inhibitors of LRRK2 kinase or abnormal LRRK2 mutant kinase and EGFR mutant kinase, in the preparation of drugs for preventing and / or treating central nervous system diseases, cancers, and immune diseases.

[0063] Among them, the central nervous system (CNS) diseases include Alzheimer's disease, L-dopa-induced dyskinesia, Parkinson's disease, ischemic stroke, traumatic brain injury or spinal cord injury; the cancers include kidney cancer, breast cancer, prostate cancer, blood cancer, papilloma, lung cancer, acute myeloid leukemia, multiple myeloma, brain cancer, etc.; the immune diseases include leprosy, Crohn's disease, inflammatory bowel disease, ulcerative colitis, amyotrophic lateral sclerosis, rheumatoid arthritis or ankylosing spondylitis.

[0064] A pharmaceutical composition comprising a heteroaryl derivative of formula I or an enantiomer, diastereomer, tautomer, solvate, polymorph, hydrate, deuterated analog, prodrug, pharmaceutically acceptable salt or excipient thereof.

[0065] The pharmaceutical composition of the present invention can also be used in combination with other drugs, wherein the other drugs are drugs for treating breast cancer.

[0066] Pharmaceutically acceptable salts of the compounds of Formula I include conventional salts formed with pharmaceutically acceptable inorganic or organic acids, or inorganic or organic bases. Examples of suitable acid addition salts include salts formed with hydrochloric acid, sulfuric acid, phosphoric acid, nitric acid, hydrobromic acid, perchloric acid, fumaric acid, acetic acid, propionic acid, succinic acid, glycolic acid, formic acid, lactic acid, maleic acid, tartaric acid, citric acid, pamoic acid, malonic acid, hydroxymaleic acid, phenylacetic acid, glutamic acid, benzoic acid, salicylic acid, fumaric acid, toluenesulfonic acid, methanesulfonic acid, naphthalene-2-sulfonic acid, benzenesulfonic acid, hydroxybenzoic acid, hydroiodic acid, malic acid, tannic acid, and the like. Examples of suitable base addition salts include salts formed with sodium, lithium, potassium, magnesium, aluminum, calcium, zinc, N,N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, N-methylglucose, and procaine.

[0067] When referring to the compounds of the present invention herein, it includes the compounds of formula I and pharmaceutically acceptable salts or solvates thereof.

[0068] The compound of formula I of the present invention can be combined with conventional pharmaceutical carriers or excipients to form a pharmaceutical composition.

[0069] The pharmaceutical composition can be administered orally or parenterally. The pharmaceutical composition of the present invention can be prepared into various dosage forms according to conventional methods in the art, including but not limited to tablets, capsules, solutions, suspensions, granules or injections, and administered orally or parenterally.

[0070] Novel structural modifications and in-depth research on the compounds of the present invention will help develop new LRRK2 kinase or abnormal LRRK2 mutant kinase inhibitors, EGFR mutant kinase inhibitors, or dual inhibitors of LRRK2 kinase or abnormal LRRK2 mutant kinase and EGFR mutant kinase, and will help develop new drugs with good application prospects and practical value. BRIEF DESCRIPTION OF THE DRAWINGS

[0071] Figure 1 shows the p-Rab10 Western Blot of compound 23 in LRRK2 R1441G MEFS;

[0072] Figure 2 shows the p-Rab10 Western Blot of compound 25 in LRRK2 R1441G MEFS;

[0073] Figure 3 shows the p-Rab10 Western Blot of compound 32 in LRRK2 R1441G MEFS;

[0074] Figure 4 is a brain tissue immunoblotting experiment (Western Blot);

[0075] FIG5 is a plasma immunoblotting experiment (Western Blot). DETAILED DESCRIPTION

[0076] The present invention will be further described in detail with reference to the following specific examples and accompanying drawings. The protection content of the present invention includes but is not limited to the following examples. The processes, conditions, reagents, experimental methods, etc. for implementing the present invention, except for those specifically mentioned below, are common knowledge and common common sense in the field and are not particularly limited by the present invention.

[0077] Example 1: Preparation of (2-((5-chloro-2-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide

[0078] Step 1: To n-butanol (50 mL) was added a suspension of 2,6-dichloro-7H-purine (2.00 g, 10.6 mmol), (2-aminophenyl)dimethylphosphine oxide (1.79 g, 10.6 mmol), and TFA (60 mg, 0.53 mmol), and the suspension was stirred at 120°C for 48 h to obtain a reaction solution. The reaction solution was cooled to room temperature, and the solvent was removed under reduced pressure. The residue was separated and purified on a silica gel column (dichloromethane / methanol = 50 / 1-20 / 1) to obtain the title compound 1c (yield 38.2%, 1.30 g, off-white solid). 1 H NMR (400MHz, DMSO): δ13.35 (s, 1H), 11.94 (s, 1H), 8.68 (d, J = 4.4Hz, 1H), 8.26 (s, 1H) ), 7.62 (dt, J = 15.6, 8.0 Hz, 2H), 7.19 ( t, J = 7.2 Hz, 1H), 1.80 ( dd, J = 13.6, 5.6 Hz, 6H).

[0079] Step 2: To n-butanol (10 mL) were added 1c (0.40 g, 1.24 mmol), 6-amino-1,4-benzodioxetine (188 mg, 1.24 mmol), and TFA (14 mg, 0.12 mmol) in sequence to obtain a suspension. The suspension was stirred at 120°C for 24 h to obtain a reaction solution. The reaction solution was cooled to room temperature, and the solvent was removed under reduced pressure. The residue was isolated and purified on a silica gel column (dichloromethane / methanol = 30 / 1 to 10 / 1) to obtain the title compound (yield 36.3%, 197 mg, as a gray solid). 1H NMR (400MHz, DMSO): δ12.61(s,1H),11.41(s,1H),8.97(dd,J=8.4,4.4Hz,1H),8.89(s,1H),7.87(s,1H),7.57 -7.52(m,3H),7.18-7.01(m,2H),6.75(d,J=8.8Hz,1H),4.21(dd,J=12.4,5.1Hz,4H),1.79(d,J=13.6Hz,6H); LC-MS(ESI)m / z: 437.1[M+H] + .

[0080] Example 2: Preparation of (2-(2-(1-methyl-1H-pyrazol-4-yl)amino)-7H-purin-6-yl)amino)phenyl)dimethylphosphine oxide

[0081] Example 2 was obtained by referring to the synthesis steps of Example 1. 1 HNMR (400MHz, DMSO-d6): δ12.56(s,1H),11.26(s,1H),8.92(s,1H),8.79(s,1H),7.88(s,1H),7.82(s,1H),7.67-7 .49(m,2H),7.47(s,1H),7.14(t,J=7.2Hz,1H),3.78(s,3H),1.80(s,3H),1.76(s,3H); LC-MS(ESI)m / z:383.0[M+H] + .

[0082] Example 3: Preparation of (2-(2-(1-methyl-1H-pyrazol-3-yl)amino)-7H-purin-6-yl)amino)phenyl)dimethylphosphine oxide

[0083] Example 3 was obtained by referring to the synthesis steps of Example 1. 1 H NMR(400MHz,DMSO-d6)δ12.53(s,1H),11.44(s,1H),9.19(s,1H),9.14-9.07(m,1H),7.86(s,1H),7.60-7.50(m,2 H),7.46(t,J=8.0Hz,1H),7.09(t,J=7.2Hz,1H),6.55(d,J=2.0Hz,1H),3.75(s,3H),1.80(s,3H),1.77(s,3H).31P NMR (162MHz, DMSO-d6) δ44.47 (s); LC-MS (ESI) m / z: 383.1[M+H]+.

[0084] Example 4: Preparation of (2-(2-((1H-indazol-6-yl)amino)-7H-purine-6-amino)phenyl)dimethylphosphine oxide

[0085] Example 4 was obtained by referring to the synthesis steps of Example 1. 1 H NMR(400MHz,DMSO-d6)δ12.76(s,1H),11.48(s,1H),9.25(s,1H),9.01(s,1H),8.11(s,1H),7.93( d,J=7.2Hz,2H),7.66-7.44(m,4H),7.39(d,J=8.4Hz,1H),7.12(s,1H),1.82(s,3H),1.78(s,3H); 31 P NMR(162MHz,DMSO-d6)δ44.53(s); LC-MS(ESI)m / z:419.25[M+H] + .

[0086] Example 5: Preparation of (2-((5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)amino)-7H-purin-6-yl)amino)phenyl)dimethylphosphine oxide

[0087] Step 1: 1-(2-amino-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)-2,2,2-trifluoroethane-1-one 5a (200 mg, 0.80 mmol) and (2-((2-chloro-7H-purin-6-yl)amino)phenyl)dimethylphosphine oxide 5b (360 mg, 0.80 mmol) were dissolved in 1,4-dioxane (5.0 mL) at room temperature. Pd2(dba)3 (148 mg, 0.16 mmol), cesium carbonate (510 mg, 1.6 mmol) and xantphos (204.74 mg, 2.13 mmol) were added to the reaction mixture under argon protection, and the temperature was raised to 110°C and stirred for 16 hours. After the reaction mixture was cooled to room temperature, it was filtered and concentrated under reduced pressure to obtain a brown solid. The residue was separated and purified by silica gel column chromatography (DCM / MeOH = 1 / 0 to 10 / 1) to obtain the target compound 5c (yield 69.28%, 313 mg, yellow solid). LC-MS (ESI) m / z: 565.1 [M+H] + .

[0088] Step 2: 5c (50 mg, 0.088 mmol) was dissolved in DCM (3 mL) at room temperature, and TFA (1 mL) was added. The reaction was stirred at room temperature for 16 h, and concentrated under reduced pressure. The residue was separated and purified by Prep-HPLC to give the title compound (15.32 mg, 40.07% yield, white solid). 1 H NMR (400MHz, DMSO-d6) δ12.80(s,1H),11.63(s,1H),9.69(s,1H),9.10(s,3H),8.23(d,J=8.4Hz,1H),8.00(s,1H),7.61(d,J=8.8H z,1H),7.58-7.49(m,1H),7.14(t,J=7.2Hz,1H),4.27(s,2H),3.56-3.49(m,2H),3.01(t,J=6.0Hz,2H),1.81(s,3H),1.78(s,3H). 31 P NMR (162MHz, DMSO-d6) δ44.72 (s); LC-MS (ESI) m / z: 435.2[M+H] + .

[0089] Example 6: Preparation of 1-(2-((6-((2-(dimethylphosphoryl)phenyl)amino)-7H-purin-2-yl)amino)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)-2,2,2-trifluoroethanone

[0090] Step 1: 5c (80 mg, 0.14 mmol) (MC22-424-048) was dissolved in dichloromethane (5.0 mL) at room temperature. DIEPA (0.5 mL, 0.28 mmol), DMAP (1.7 mg, 0.014 mmol), and TFAA (88.3 mg, 0.42 mmol) were added to the reaction mixture at 0°C. The mixture was heated to 25°C and stirred for 2 hours. After completion of the reaction, water (10 mL) was added and the mixture was extracted with ethyl acetate (10 mL x 2). The organic phase was washed with saturated brine and concentrated under reduced pressure. The residue was isolated and purified by silica gel column chromatography (DCM / MeOH = 1 / 0 to 10 / 1) to obtain the target compound 6a (yield 64.93%, 68 mg, yellow solid). LC-MS (ESI) m / z: 661.0 [M+H] + .

[0091] Step 2: 6a (50 mg, 0.088 mmol) was dissolved in DCM (3 mL) at room temperature, and TFA (1 mL) was added. The reaction was stirred at room temperature for 16 h, and concentrated under reduced pressure. The residue was separated and purified by Prep-HPLC to give the title compound (10.23 mg, yield 19.3%, white solid). 1 H NMR(400MHz,DMSO-d6)δ11.69(s,1H),8.94(s,1H),8.10(s,1H),7.96(s,1H),7.84(s,1H),7.72-7.45(m,2H),7.1 8(t,J=6.6Hz,1H),4.78(d,J=9.4Hz,2H),3.94(d,J=5.6Hz,4H),2.96(d,J=14.8Hz,2H),1.82(s,3H),1.79(s,3H); 19 F NMR(377MHz, DMSO-d6)δ-68.40(s),-74.23(s); 31 P NMR (162MHz, DMSO-d6) δ44.49; LC-MS (ESI) m / z: 531.0[M+H] + .

[0092] Example 7: Preparation of 1-(2-((6-((2-(dimethylphosphoryl)phenyl)amino)-7H-purin-2-yl)amino)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)-2-hydroxyethane-1-one

[0093] Step 1: 5c (70 mg, 0.12 mmol) and 2-hydroxyacetic acid (74.5 mg, 0.98 mmol) were dissolved in DMF (5.0 mL) at room temperature. DIEPA (1.3 mL, 0.6 mmol) and HATU (221.3 mg, 0.42 mmol) were added to the reaction mixture, and the mixture was stirred at 25°C for 1 hour. After completion of the reaction, water (10 mL) was added, and the mixture was extracted with ethyl acetate (10 mL x 2). The organic phase was washed with saturated brine and concentrated under reduced pressure. The residue was isolated and purified by silica gel column chromatography (DCM / MeOH = 1 / 0-10 / 1) to obtain the target compound 7a (yield 85.11%, 90 mg, white solid). LC-MS (ESI) m / z: 623.1 [M+H] + .

[0094] Step 2: 7a (90 mg, 0.14 mmol) (MC22-424-056) was dissolved in DCM (3 mL) at room temperature. TFA (1 mL) was added and the reaction was stirred at room temperature for 16 hours. The mixture was concentrated under reduced pressure and the residue was purified by Prep-HPLC to afford the title compound 7 (18.89 mg, 27.39% yield, white solid). 1 H NMR (400MHz, DMSO-d6) δ12.82(s,1H),11.62(s,1H),9.56(s,1H),9.11(s,1H),8.13(s,1H),7.99(s,1H),7.74-7.43(m,4H),7.13(t,J=7.2Hz ,1H),4.58(d,J=28Hz,2H),4.20(d,J=12..4Hz,2H),3.82(s,1H),3.70(t,J=5.6Hz,1H),2.89(s,1H),2.81(s,1H),1.81(s,3H),1.78(s,3H); 31 P NMR (162MHz, DMSO-d6) δ44.69 (s); LC-MS (ESI) m / z: 493.0 [M+H] + .

[0095] Example 8: Preparation of dimethyl (2-((2-((5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)amino)-7H-purin-6-yl)amino)phenyl)phosphine oxide

[0096] Step 1: 5-Methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-amine (49.01 mg, 0.29 mmol) and 5b (90 mg, 0.19 mmol) were dissolved in 1,4-dioxane (10.0 mL) at room temperature. Brettphos G3Pd (18.12 mg, 0.02 mmol) and sodium tert-butoxide (39.4 mg, 0.40 mmol) were added to the reaction mixture under argon. The mixture was heated to 110°C and stirred for 3 hours. After cooling to room temperature, the reaction mixture was filtered and concentrated under reduced pressure to obtain a brown solid. The residue was isolated and purified by silica gel column chromatography (DCM / MeOH = 1 / 0 to 15 / 1) to obtain the target compound 8b (yield 52.24%, 180 mg, red solid). LC-MS (ESI) m / z: 585.1 [M+H] + .

[0097] Step 2: 8b (180 mg, 0.3 mmol) was dissolved in DCM (3.00 mL) at room temperature. TFA (1.00 mL) was slowly added dropwise to the solution. The reaction was stirred at room temperature for 3 h. After the reaction was completed, the product was concentrated under reduced pressure. The residue was separated and purified by Prep-HPLC to obtain the title compound (45.38 mg, 33.32% yield, yellow solid). 1 H NMR(400MHz,DMSO-d6)δ12.93(s,1H),11.60(s,1H),11.44(s,1H),9.01(s,1H),8.03(s,1H),7.67-7.57(m,1H) ,7.53(t,J=7.7Hz,1H),7.18(t,J=7.2Hz,1H),4.36(s,2H),3.52(s,2H),2.93(s,5H),1.80(s,3H),1.77(s,3H); 31 P NMR (162MHz, DMSO-d6) δ43.88 (s); LC-MS (ESI) m / z: 455.0 [M+H] + .

[0098] Example 9: Preparation of 6-((6-((2-(dimethylphosphoryl)phenyl)amino)-7H-purin-2-yl)amino)-3,4-dihydroquinolin-2(1H)-one

[0099] To a solution of 6-amino-3,4-dihydroquinolin-2(1H)-one (0.20 g, 1.23 mmol) and 1c (0.40 g, 1.23 mmol) in n-BuOH (40 mL) at room temperature was added TsOH·H2O (20 mg, 10 wt%). After argon replacement three times, the mixture was heated to 120°C and stirred for 48 h. TLC monitored the reaction for completion. The reaction mixture was cooled to room temperature and concentrated under reduced pressure to afford a brown oil, which was purified by silica gel column chromatography (DCM / MeOH = 1 / 0 to 30 / 1) to afford the title compound 9 (yield 34.4%, 190 mg, as a gray solid). 1 H NMR (400MHz, DMSO) δ12.59(s,1H),11.39(s,1H),9.91(s,1H),9.02-8.76(m,2H),7.89(s,1H),7.66-7.36(m,4 H),7.18-7.05(m,1H),6.76(d,J=8.4Hz,1H),2.82(t,J=7.6Hz,2H),2.48-2.37(m,2H),1.79(d,J=13.6Hz,6H); 31P NMR (162MHz, DMSO) δ44.24 (s); LC-MS (ESI) m / z: 448.2[M+H]+.

[0100] Example 10: Preparation of (2-((2-(1,2,3,4-tetrahydroquinolin-6-yl)amino)-7H-purin-6-yl)amino)phenyl)dimethylphosphine oxide

[0101] To a solution of compound 9 (50 mg, 0.11 mmol) in THF (5 mL) at room temperature was added BH3·Me2S (0.55 mL, 2 M in THF, 1.12 mmol). The mixture was heated to 50°C and stirred for 4 h. TLC confirmed the reaction was complete. The reaction mixture was cooled to room temperature, and methanol (10 mL) was slowly added dropwise. The mixture was heated under reflux for 0.5 h. The mixture was cooled to room temperature, and dilute hydrochloric acid (6 M, 10 mL) was added. The mixture was heated under reflux for 0.5 h. The reaction mixture was concentrated under reduced pressure to obtain a brown solid. Purification by silica gel column chromatography afforded the title compound (yield 48.8%, 23.65 mg, brown solid). 1 H NMR (400MHz, DMSO) δ12.44(s,1H),11.35(s,1H),8.96(s,1H),8.48(s,1H),7.80(s,1H),7.54(dd,J=14.4,7.4Hz,1H),7.43(t,J=7.6Hz,1H),7.10 (dd,J=21.6,14.1Hz,3H),6.38(d,J=8.8Hz,1H),5.30(s,1H),3.39(d,J= 5.2Hz,2H),3.21-3.10(m,2H),2.69-2.58(m,2H),1.78(d,J=13.6Hz,6H); 31 P NMR (162MHz, DMSO) δ44.29 (s); LC-MS (ESI) m / z: 434.2[M+H]+.

[0102] Example 11: Preparation of 7-((6-((2-(dimethylphosphoryl)phenyl)amino)-7H-purin-2-yl)amino)-3,4-dihydroquinolin-2(1H)-one

[0103] Example 11 was obtained by referring to the synthetic steps of Example 9.

[0104] 1H NMR (400MHz, DMSO) δ12.61(s,1H),11.44(s,1H),10.02(s,1H),9.06(s,1H),8.98(dd,J=7.6,4.1Hz,1H),7.90( s,1H),7.62-7.36(m,3H),7.16-7.00(m,3H),2.82(t,J=7.6Hz,2H),2.48-2.39(m,2H),1.79(d,J=13.6Hz,6H); 31 P NMR (162MHz, DMSO) δ44.46 (s); LC-MS (ESI) m / z: 448.2[M+H]+.

[0105] Example 12: Preparation of (2-((2-(1,2,3,4-tetrahydroquinolin-7-yl)amino)-7H-purin-6-yl)amino)phenyl)dimethylphosphine oxide

[0106] Example 12 was obtained by referring to the synthetic steps of Example 10. 1 H NMR (400MHz, DMSO) δ12.53(s,1H),11.39(s,1H),9.02(s,1H),8.67(s,1H),7.85(s,1H),7.61-7.44(m,2H),7.10(t,J=7.2Hz,1H),6.91(d,J =6.4Hz,1H),6.72(d,J=7.6Hz,2H),5.41(s,1H),4.43(s,1H),3.39(s,2H),3.21-3.12(m,2H),2.62(t,J=6.0Hz,2H),1.78(d,J=13.6Hz,6H); 31 P NMR (162MHz, DMSO) δ44.36 (s); LC-MS (ESI) m / z: 434.2[M+H]+.

[0107] Example 13: Preparation of 2-(4-((6-((2-(dimethylphosphoryl)phenyl)amino)-7H-purin-2-yl)amino)-3-methyl-1H-pyrazol-1-yl)-2-methylpropionitrile

[0108] Example 12 was obtained by referring to the synthesis steps of Example 8. 1H NMR(400MHz,DMSO-d6)δ12.55(s,1H),11.41(s,1H),8.80(s,1H),8.32(s,1H),7.98 -7.95(m,2H),7.74-7.35(m,2H),7.09(t,J=7.2Hz,1H),2.16(s,3H),1.93(s,6H),1.79(d,J=13.4Hz,6H). 31 P NMR (162MHz, DMSO) δ44.34 (s); LC-MS (ESI) m / z: 450.2 [M+H] + .

[0109] Example 14: Preparation of (2-((6-(((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide

[0110] Step 1: To a solution of 4,6-dichloro-1H-pyrazolo[3,4-d]pyrimidine 14a (2.00 g, 10.6 mmol) in THF (40 mL) was added DHP (1.07 g, 12.7 mmol) and TsOH·H₂O (100 mg, 0.53 mmol) at room temperature. The mixture was heated to 40°C and stirred for 6 h. The reaction was monitored for completion by TLC. The reaction mixture was cooled to room temperature and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (PE / EA = 1 / 0 to 10 / 1) to afford the target compound 14b (yield 72.7%, 2.10 g, as a white solid). 1 H NMR(400MHz, CDCl3)δ8.19(s,1H),6.00(dd,J=10.4,2.5Hz,1H),4.12(dd,J=10.4,3.1Hz,1H),3.80(td,J=11.6,2.4Hz, 1H),2.65-2.46(m,1H),2.14(dd,J=9.6,3.6Hz,1H),1.95(dd,J=12.4,2.8Hz,1H),1.83-1.71(m,2H),1.70-1.61(m,1H).

[0111] Step 2: To a solution of 14b (0.50 g, 1.83 mmol) in NMP (10 mL) at room temperature were added (2-aminophenyl)dimethylphosphine oxide (0.31 g, 1.83 mmol) and DIEA (0.71 g, 5.49 mmol). The atmosphere was replaced with argon three times, and the mixture was heated to 80°C and stirred for 4 h. The reaction was monitored for completion by TLC. The reaction mixture was cooled to room temperature, poured into ice water (50 mL), and extracted with EA (50 mL × 3). The organic phase was washed with saturated aqueous NaCl (100 mL × 3), dried over anhydrous sodium sulfate, and concentrated to afford a brown oil. Purification by silica gel column chromatography (PE / EA = 1 / 0-1 / 2) afforded the title compound (yield 28.3%, 210 mg, white solid). LC-MS (ESI) m / z: 406.0 [M+H]+.

[0112] Step 3: Synthesize the target compound 14d (yield 41.3%, 53 mg, brown solid) by referring to Step 1 of Example 5. LC-MS (ESI) m / z: 521.1 [M+H] + .

[0113] Step 4: Under argon, HCl / MeOH (1 mL, 4 M) was added to a solution of 14d (85 mg, 0.15 mmol) in methanol (2 mL). The mixture was stirred at room temperature for 3 h. TLC monitored the reaction for completion. The reaction solution was concentrated under reduced pressure to yield a brown oil, which was purified by Prep-TLC (DCM / MeOH / NH3·H2O = 10 / 1 / 0.001) to afford the title compound 14 (yield 42.5%, 30.3 mg, brown solid). 1 H NMR (400MHz, DMSO) δ13.06(s,1H),12.05(s,1H),9.15(s,1H),9.02(s,1H),7.74(s,1H),7.62(dd,J=13.6,7.7Hz,1H 31P NMR (162MHz, DMSO) δ47.95 (s); LC-MS (ESI) m / z: 437.1[M+H]+.

[0114] Example 15: Preparation of (2-((6-(((5-methyl-4,5,6,7-tetrahydrothiazol[5,4-c]pyridin-2-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide

[0115] Example 15 was obtained by referring to the synthesis steps of Example 14, wherein in step 3, Cs2CO3 was replaced by KCO3, and the other steps remained unchanged. 1 H NMR(400MHz,MeOD)δ8.50(s,1H),7.97(dd,J=12.8,8.0Hz,1H),7.82(t,J=6.4Hz,2H),7.70(dd,J=7.2,5.6Hz,1H),4 .23(d,J=58.4Hz,2H),3.78(s,1H),3.50(s,1H),2.98(s,2H),1.80(d,J=13.6Hz,6H); LC-MS(ESI)m / z:455.2[M+H]+.

[0116] Example 16: (2-((6-((6-propylamino)-4,5,6,7-tetrahydrobenzo[d]thiazol-2-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide

[0117] Example 16 was obtained by referring to the synthetic steps of Example 15. 1 H NMR (400MHz, DMSO) δ13.31(s,1H),12.16(s,1H),11.28(s,1H),9.11(s,1H),7.81(s,1H),7.64(dd,J=13 .6,8.0Hz,1H),7.54(t,J=7.6Hz,1H),7.19(t,J=7.2Hz,1H),4.10(d,J=4.8Hz,1H),3.17(d,J=4.4Hz,1H ),2.91(d,J=11.6Hz,2H),2.65(d,J=16.8Hz,1H),2.58(t,J=7.2Hz,2H),2.39(dd,J=16.0,8.4Hz,1H),1 .99(s,1H),1.81(t,J=20.4Hz,6H),1.59(d,J=7.2Hz,1H),1.51-1.34(m,2H),0.89(t,J=7.2Hz,3H); 31P NMR (162MHz, DMSO) δ48.00-47.19 (m); LC-MS (ESI) m / z: 497.3[M+H]+.

[0118] Example 17: Preparation of 1-(2-((4-((2-(dimethylphosphoryl)phenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-6-yl)amino)-7,8-dihydro-1,6-naphthyridin-6(5H)yl)-2,2,2-trifluoroethanone

[0119] Step 1: Compound 17a was synthesized by referring to Step 1 of Example 8 (yield 20.95%, 103 mg, yellow solid). LC-MS (ESI) m / z: 615.0 [M+H] + .

[0120] Step 2: 17a (50 mg, 0.08 mmol) was dissolved in MeOH (1.00 mL) at room temperature. 4N HCl / MeOH (2.00 mL) was slowly added dropwise to the solution. The reaction was stirred at room temperature for 16 h and concentrated under reduced pressure. The residue was separated and purified by Prep-HPLC to give the title compound (3.84 mg, 9.05% yield, as a white solid). 1 H NMR(400MHz,MeOD-d4)δ8.71(s,1H),8.50-8.14(m,1H),7.92(s,1H),7.82-7.66(m,2H),7.4 3(s,1H),7.31(s,1H),4.07(s,2H),3.35(s,2H),3.26-3.20(m,2H),1.92(d,J=13.6Hz,6H). 19 F NMR(377MHz,MeOD-d4)δ-70.92(d,J=39.0Hz),-77.17(s); 31 P NMR (162MHz, MeOD-d4) δ67.56-61.58 (m); LC-MS (ESI) m / z: 531.2[M+H] + .

[0121] Example 18: Preparation of (2-((6-((5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide

[0122] Step 1: Using 5a and 14c as starting materials, the intermediate product was synthesized according to Step 1 of Example 8 (yield 30.13%, 125 mg, yellow solid). LC-MS (ESI) m / z: 519.0 [M+H] + .

[0123] Step 2: Refer to step 2 of Example 17 to synthesize the target product. 1H NMR(400MHz,MeOD-d4)δ8.67(s,1H),8.30(s,1H),7.87-7.63(m,3H),7.62-7.33(m,2H),4.42(s,2H),3.67(t,J=6.2Hz , 2H), 3.33 (s, 4H), 1.92 (d, J = 13.6Hz, 6H); 31PNMR (162MHz, MeOD-d4) δ 48.36-43.37 (m); LC-MS (ESI) m / z: 435.3[M+H]+.

[0124] Example 19: Preparation of 1-(3-((4-((2-(dimethylphosphoryl)phenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-6-yl)amino)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)-2-hydroxyethane-1-one

[0125] Example 19 was synthesized by using the product of step 1 of Example 18 as a raw material and referring to step 1 of Example 7 and step 4 of Example 14. 1 H NMR (400MHz, DMSO) δ14.30(s,1H),13.24(s,1H),10.80(s,1H),10.26(s,1H),9.49(s,1H),9.33(d,J=8.4Hz,1H),8.85(s,1H),8.73-8.51( m,2H),8.21(t,J=7.2Hz,1H),5.64(d,J=27.6Hz,2H),5.26(d,J=11.6Hz,2H),4.75(s,2H),3.91(d,J=32.0Hz,2H),2.91(d,J=13.6Hz,6H); 31 P NMR (162MHz, MeOD-d4) δ 49.35 (s); LC-MS (ESI) m / z: 493.1 [M+H] + .

[0126] Example 20: Preparation of (2-((2-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide

[0127] Step 1: 2,4-Dichloro-7H-pyrrolo[2,3-d]pyrimidine (2 g, 10.64 mmol) and DIEA (2.744 g, 10.638 mmol) were dissolved in DMF (40.0 mL) at room temperature. SEM-Cl (2.744 g, 21.28 mmol) was added to the reaction mixture at 0°C and stirred at room temperature for 2 hours. After the reaction was completed, water (50 mL) was added and the mixture was extracted with ethyl acetate (50 mL x 2). The organic phase was washed with saturated brine and concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography (PE / EA = 1 / 0-2 / 1) to obtain the title compound (yield 84.45%, 2.86 g, transparent oil). LC-MS (ESI) m / z: 318.0 [M+H]+.

[0128] Step 2: 2,4-Dichloro-7-(2-trimethylsilylethoxy)methyl-7H-pyrrolo[2,3-d]pyrimidine (2.0 g, 6.28 mmol) (MC22-424-096) and (2-aminophenyl)dimethylphosphine oxide were dissolved in DMF (40 mL) at room temperature. Potassium tert-butoxide (1.408 g, 12.56 mmol) was added and the mixture was stirred at 0°C for 2 hours. After completion of the reaction, water (80 mL) was added to quench the reaction. The mixture was extracted with ethyl acetate (100 mL x 2). The organic phase was washed with saturated brine and concentrated under reduced pressure. The residue was isolated and purified by silica gel column chromatography (PE / EA = 1 / 0-2 / 1) to obtain the title compound (yield 84.45%, 2.86 g, gray solid). LC-MS (ESI) m / z: 451.0 [M+H]+.

[0129] Step 3: Refer to the synthesis step 1 of Example 8 to obtain 20d. LC-MS (ESI) m / z: 566.0 [M+H] + .

[0130] Step 4: 20d (148 mg) was dissolved in DCM (3.00 mL), TFA (1.00 mL) was slowly added dropwise to the solution, and the reaction was stirred at room temperature for 3 hours. After the reaction was completed, the solution was concentrated under reduced pressure. The residue was dissolved in MeOH (2.50 mL), NH3H2O ​​(2.50 mL) was slowly added dropwise to the solution, and the reaction was stirred at room temperature for 6 hours. After the reaction was completed, the solution was concentrated under reduced pressure. The residue was separated and purified by Prep-HPLC to obtain the title compound (31.24 mg, yield 24.13%, white solid). 1H NMR(400MHz,MeOD-d4)δ8.88-8.75(m,1H),7.68-7.39(m,2H),7.32(d,J=2.4Hz,1H),7.17-7.07(m,1H),6.98-6.91 (m,1H),6.86(d,J=3.6Hz,1H),6.71(d,J=8.8Hz,1H),6.40(d,J=3.6Hz,1H),4.24-4.18(m,4H),1.88-1.83(m,6H); 31 P NMR(162MHz,MeOD-d4)δ49.22(s); LC-MS(ESI)m / z: 436.05[M+H] + .

[0131] Example 21: Preparation of (2-((2-((5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide

[0132] Step 1: Refer to the synthetic step 1 of Example 8 to obtain the product with a protected group. LC-MS (ESI) m / z: 584.1 [M+H] + .

[0133] Step 2: Refer to the synthesis step 4 of Example 20 to obtain the target product. 1 H NMR(400MHz,DMSO-d6)δ11.76(s,1H),11.51(s,1H),11.03(s,1H),9.33 -9.10(m,1H),7.63-7.53(m,1H),7.50(t,J=7.8Hz,1H),7.10(t,J=7.2Hz,1H),7.05-6.99(m,1H),6.4 5-6.39(m,1H),3.58(s,2H),2.78(d,J=5.4Hz,2H),2.67(s,2H),2.44(s,3H),1.83(d,J=13.6Hz,6H); 31 P NMR (162MHz, DMSO-d6) δ47.07 (s); LC-MS (ESI) m / z: 454.0 [M+H] + .

[0134] Example 22: Preparation of 1-(2-((4-((2-(dimethylphosphoryl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)-2-hydroxyethane-1-one

[0135] Example 22 was synthesized by referring to step 1 of Example 7 and step 4 of Example 20. 1 H NMR (400MHz, DMSO-d6) δ11.93-11.90(m,2H),9.03(s,1H),7.84(d,J=26.8Hz,2H),7.70-7.50(m,2H),7.26-7.11(m, 2H),6.49(s,1H),4.62(d,J=21.6Hz,2H),4.22(d,J=16.4Hz,2H),3.74(s,2H),3.00(s,2H),1.85(d,J=13.6Hz,6H); 31 P NMR (162MHz, DMSO-d6) δ47.15 (s); LC-MS (ESI) m / z: 492.3[M+H] + .

[0136] Example 23: Preparation of 1-(2-((4-((2-(dimethylphosphoryl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)-2-2,2,2-trifluoroethanone

[0137] Example 24 was dissolved in DCM (5.00 mL) at room temperature, and TEA (68.8 mg, 0.68 mmol) and TFAA (214 mg, 1.02 mmol) were added to the solution. The reaction was stirred at room temperature for 1 hour. After the reaction was completed, the mixture was concentrated under reduced pressure. The residue was separated and purified by Prep-HPLC to obtain the title compound (6.23 mg, yield 3.46%, white solid). 1 H NMR(400MHz,DMSO-d6)δ12.02(s,1H),11.88(s,1H),9.03(s,1H),7.89(s,2H),7.71-7.52(m,2H),7.18(s,2H ), 6.50 (s, 1H), 4.79 (d, J = 9.6Hz, 2H), 3.96 (d, J = 6.0Hz, 2H), 3.03 (d, J = 14.0Hz, 2H), 1.85 (d, J = 13.6Hz, 6H); 19 F NMR(377MHz, DMSO-d6)δ-68.45(d,J=30.1Hz),-74.01(s); 31 P NMR (162MHz, DMSO-d6) δ47.09 (s); LC-MS (ESI) m / z: 530.1[M+H] + .

[0138] Example 24: Preparation of (2-((5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide

[0139] The target product 24 was obtained by deprotection according to step 1 of Example 8 and step 4 of Example 20. 1 H NMR (400MHz, DMSO-d6) δ11.96(s,1H),11.77(s,1H),10.24(s,1H),9.21(s,1H),9.11(s,1H),8.04(s,1H),7.72(d,J=8.3Hz,1H),7.62(dd,J =14.2,7.6Hz,1H),7.55(t,J=7.8Hz,1H),7.13(s,1H),6.47(s,1H),4.29(s,2H),3.53(s,2H),3.07(d,J=5.9Hz,2H),1.84(d,J=13.6Hz,6H); 31 P NMR (162MHz, DMSO-d6) δ47.15 (s); LC-MS (ESI) m / z: 434.2[M+H] + .

[0140] Example 25: Preparation of 2-(4-((4-)((2-(dimethylphosphoryl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methyl-1H-pyrazol-1-yl)-2-methylpropionitrile

[0141] Step 1: 2-(4-amino-3-methyl-1H-pyrazol-1-yl)-2-methylpropionitrile and 20c were used as starting materials to obtain the protected product according to Step 1 of Reference Example 8. LC-MS (ESI) m / z: 579.3 [M+H] + .

[0142] Step 2: Deprotection was performed according to step 4 of Example 20 to obtain the target product. 1H NMR (400MHz, CDCl3) δ11.36-11.17(m,1H),9.27-8.97(m,1H),8.78-8.62(m,1H),8.20-8.02(m,1H),7.61-7.50(m,1H),7.30-7.26(m ,1H),7.25-7.22(m,1H),7.15-7.04(m,1H),6.60-6.42(m,1H),6.41-6.31(m,1H),2.29(s,3H),1.98(s,6H),1.88(d,J=13.2Hz,6H); 31 P NMR(162MHz, CDCl3)δ48.08-47.28(m); LC-MS(ESI)m / z:449.1[M+H] + .

[0143] Example 26: Preparation of 6-((4-((2-(dimethylphosphoryl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3,4-dihydroquinolin-2(H)-one

[0144] Example 26 was obtained by referring to the synthetic steps of Example 9. 1 H NMR (400MHz, DMSO) δ11.96(s,1H),11.77(s,1H),10.24(s,1H),9.21(s,1H),9.11(s,1H),8.04(s,1H),7.72(d,J=8.3Hz,1H),7.62(dd,J=14.2,7. 6Hz,1H),7.55(t,J=7.8Hz,1H),7.13(s,1H),6.47(s,1H),6.76(d,J=8.4 Hz,1H),2.82(t,J=7.6Hz,2H),2.48-2.37(m,2H),1.80(d,J=13.6Hz,6H); 31 P NMR (162MHz, DMSO) δ47.12 (s); LC-MS (ESI) m / z: 447.2[M+H]+.

[0145] Example 27: Preparation of (2-((1,2,3,4-tetrahydroquinolin-6-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)aminophenyl)dimethylphosphine oxide

[0146] Example 27 was obtained by referring to the synthetic steps of Example 10. 1H NMR (400MHz, DMSO-d6) δ8.88-8.75(m,1H),7.68-7.39(m,2H),7.32(d,J=2.4Hz,1H),7.17-7.07(m,1H),6.98-6.91(m,1H),6.86(d,J=3.6 Hz,1H),6.71(d,J=8.8Hz,1H),6.40(d,J=3.6Hz,1H),3.39(d,J=5.2Hz,2H),3.21-3.10(m,2H),2.69-2.58(m,2H),1.78(d,J=13.6Hz,6H); 31 P NMR (162MHz, DMSO) δ47.26 (s); LC-MS (ESI) m / z: 433.2[M+H]+.

[0147] Example 28: Preparation of 7-((4-((2-(dimethylphosphoryl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3,4-dihydroquinolin-2(1H)-one

[0148] Example 28 was obtained by referring to the synthetic steps of Example 9. 1 H NMR (400MHz, DMSO) δ11.96(s,1H),11.77(s,1H),10.24(s,1H),9.21(s,1H),9.11(s,1H),8.04(s,1H),7.72(d,J=8.3Hz,1H),7.62(dd,J=14.2,7. 6Hz,1H),7.55(t,J=7.8Hz,1H),7.13(s,1H),6.47(s,1H),6.76(d,J=8.4 Hz,1H),2.82(t,J=7.6Hz,2H),2.48-2.39(m,2H),1.79(d,J=13.6Hz,6H); 31 P NMR (162MHz, DMSO) δ47.36 (s); LC-MS (ESI) m / z: 447.2[M+H]+.

[0149] Example 29: Preparation of (2-(((1,2,3,4-tetrahydroquinolin-7-yl)amino)7H-pyrrolo[2,3-d]pyrimidin-4-yl)aminophenyl)dimethylphosphine oxide

[0150] Example 29 was obtained by referring to the synthetic steps of Example 10. 1H NMR (400MHz, DMSO) δ8.88-8.75(m,1H),7.68-7.39(m,2H),7.32(d,J=2.4Hz,1H),7.17-7.07(m,1H),6.98-6.91(m,1H),6.86(d,J=3. 6Hz,1H),6.71(d,J=8.8Hz,1H),6.40(d,J=3.6Hz,1H),3.39(s,2H),3.21-3.12(m,2H),2.62(t,J=6.0Hz,2H),1.78(d,J=13.6Hz,6H); 31 P NMR (162MHz, DMSO) δ47.13 (s); LC-MS (ESI) m / z: 433.2[M+H]+.

[0151] Example 30: Preparation of 1-(2-((4-((2-(dimethylphosphoryl)phenyl)amino)-5H-pyrrolo[3,2-d]pyrimidin-2-yl)amino)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)-2-hydroxyethane-1-one

[0152] Referring to the synthesis steps 1 and 2 of Example 20, (2-((2-chloro-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide was obtained, and then the target product was obtained by referring to the synthesis steps 1 of Example 8 and 22 of Example 5a. 1 H NMR (400MHz, MeOD-d4) δ8.47-8.40(m,1H),7.79-7.64(m,4H),7.43(t,J=7.0Hz,1H),7.06(d,J=8.5Hz,1H),6.71-6.63(m,1H),4.75(s, 1H),4.63(s,1H),4.38(s,1H),4.34(s,1H),3.99(s,1H),3.81(d,J=6.0Hz,1H),3.36(s,1H),3.24-3.07(m,2H),1.90(d,J=13.6Hz,6H); 31 P NMR(162MHz,MeOD-d4)δ49.01-47.51(m); LC-MS(ESI)m / z: 492.1[M+H] + .

[0153] Example 31: Preparation of 2-(2-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)amino)-5H-pyrrolo[3,2-d]pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide

[0154] Example 31 was obtained by referring to the synthetic steps of Example 20. 1 H NMR (400MHz, MeOD) δ8.38-8.31(m,1H),7.72-7.52(m,2H),7.48(d,J=2.8Hz,1H),7.32(t,J=6.8Hz,1H),7.02(d,J =2.4Hz,1H),6.87-6.81(m,1H),6.78(d,J=8.8Hz,1H),6.33(d,J=2.8Hz,1H),4.24(s,4H),1.87(d,J=13.6Hz,6H); 31 P NMR (162MHz, MeOD) δ48.29 (s); LC-MS (ESI) m / z: 436.0 [M+H] + .

[0155] Example 32: Preparation of (2-((5-chloro-2-((6-(propylamino)-4,5,6,7-tetrahydrobenzothiazol-2-yl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide

[0156] Using tert-butyl (2-amino-4,5,6,7-tetrahydrobenzo [d] thiazol-6-yl) (propyl) carbamate as raw material, Example 15 was obtained by referring to the synthesis steps of Example 14, wherein in step 3, KCO3 was used to replace Cs2CO3, and the other steps remained unchanged. 1 H NMR (400MHz, MeOD): δ8.54(s,1H),8.27(s,1H),7.84-7.54(m,2H),7.37(t,J=7.2Hz,1H),3.50(s,1H), 3.08-3.04(m,3H),2.87-2.51(m,3H),2.30(d,J=10.8Hz,1H),2.05-1.61(m,9H),1.06(t,J=7.2Hz,3H); 31 P NMR (162MHz, MeOD) δ45.94 (s); LC-MS (ESI) m / z: 491.0 [M+H]+.

[0157] Example 33: Preparation of 1-(2-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)-2,2,2-trifluoroethanone

[0158] To a solution of 1-(2-amino-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)-2,2,2-trifluoroethane-1-one (400 mg, 1.63 mmol) in toluene (20 mL) were added (2-(2,5-dichloropyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide (515 mg, 1.63 mmol), Pd2dba3 (74 mg, 0.08 mmol), BINAP (105 mg, 0.16 mmol), and Cs2CO3 (1.06 g, 3.26 mmol) under argon. The mixture was replaced with nitrogen and heated to 100°C and stirred for 13 h. After the reaction mixture was cooled to room temperature, it was filtered through celite and concentrated under reduced pressure. The residue was purified and separated by silica gel column chromatography (PE / EA=1 / 0-1 / 1) to give the target compound 33 (yield: 5.2%, 44.2 mg, yellow solid). 1 H NMR (400MHz, DMSO) δ11.38(s,1H),9.87(d,J=3.2Hz,1H),8.84(s,1H),8.25(s,1H),8.00(d,J=8.8Hz,1H),7.62-7.56(m,3H),7.18(t,J=7 .2Hz, 1H), 4.74 (d, J = 10.0Hz, 2H), 4.05-3.75 (m, 2H), 2.93 (dd, J = 12.4, 6.0Hz, 2H), 1.79 (d, J = 13.6Hz, 6H); LC-MS (ESI) m / z: 525.2 [M+H]+.

[0159] Example 34: Preparation of (2-(5-chloro-2-((5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)amino)pyrimidin-4-yl)amine)phenyldimethylphosphine oxide

[0160] 1-(2-(5-chloro-4-(2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)-2,2,2-trifluoroethane-1-one (57 mg, 0.108 mmol) was dissolved in THF (1 mL) and MeOH (2 mL) at room temperature, and K2CO3 (45 mg, 0.325 mmol) was added. The mixture was stirred at 60°C for 3 h. The reaction was complete as monitored by TLC (DCM / MeOH = 15 / 1). After the reaction mixture was cooled to room temperature, it was quenched and diluted with water (20 mL) and extracted with DCM (20 mL × 3). The organic phase was washed with saturated aqueous NaCl solution (20 mL × 3), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified and isolated by Prep-HPLC to obtain the target compound 34 (yield: 58.8%, 27.4 mg, white solid). 1 H NMR (400MHz, DMSO) δ11.41(s,1H),9.96(s,1H),9.11(s,2H),8.86(dd,J=8.4,4.0Hz,1H),8.26(s,1H),8.02(d,J=8.8Hz,1H),7.69-7.45(m, 3H), 7.19 (t, J = 7.2Hz, 1H), 4.26 (s, 2H), 3.50 (t, J = 6.4Hz, 2H), 3.00 (t, J = 6.0Hz, 2H), 1.79 (d, J = 13.6Hz, 6H); LC-MS (ESI) m / z: 429.0 [M+H]+.

[0161] Example 35: Preparation of (2-((5-chloro-2-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide

[0162] Example 35 was obtained by referring to the synthesis steps of Example 1. 1 H NMR (400MHz, CDCl3) δ10.89(s,1H),8.64-8.61(m,1H),7.49(t,J=8.0Hz,1H),7.31-7.23(m,2H),7.19(d,J=2.4Hz ,1H),7.14-7.07(m,1H),6.92-6.90(m,2H),6.80(d,J=8.8Hz,1H),4.26(d,J=2.4Hz,4H),1.83(d,J=13.2Hz,6H); 31 P NMR(162MHz,MeOD)δ44.02(s); LC-MS(ESI)m / z:431.1[M+H] + .

[0163] Example 36: Preparation of 1-(2-(5-chloro-4-(2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)-2-hydroxyethane-1-one

[0164] Using Example 34 as the starting material, the target compound 36 was obtained by referring to Step 1 of Example 7. 1 H NMR (400MHz, DMSO) δ11.37(s,1H),9.79(s,1H),8.86(d,J=14.8Hz,1H),8.2 4(s,1H),7.95(d,J=7.2Hz,1H),7.53(dd,J=14.8,8.4Hz,3H),7.18(s,1H),4 .60(s,2H),4.54(s,1H),4.25-4.14(m,2H),3.79(s,1H),3.68(s,1H),2.88 (s, 1H), 2.80 (s, 1H), 1.79 (d, J = 13.6Hz, 6H); LC-MS (ESI) m / z: 487.2[M+H]+.

[0165] Example 37: Preparation of (2-((5-chloro-2-((6-methyl-5,6,7,8-tetrahydro-4H-thiazolo[4,5-d]azepin-2-yl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide

[0166] The target compound 37 was synthesized by referring to step 1 of Example 8. 1 H NMR (400MHz, MeOD): δ8.26(s,1H),8.05(s,1H),7.84-7.54(m,2H),7.37(t,J=7.2Hz,1H ),2.65-3.69(m,8H),2.82(s,3H),1.72(d,J=13.6Hz,6H); LC-MS(ESI)m / z:463.2[M+H] + .

[0167] Example 38: Preparation of (2-((-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-7,8-dihydro-4H-thiazolo[4,5-d]azepin-6(5H)-yl)(tetrahydro-2H-pyran-4-yl)methanone

[0168] Using Example 37 as the starting material, the deprotection was carried out according to Example 34, and then the target compound 38 was obtained according to Step 1 of Example 7. 1H NMR (400MHz, MeOD): δ8.52(s,1H),8.09(s,1H),7.72-7.43(m,2H),7.35(t,J=7.2Hz,1H ),2.65-3.65(m,16H),2.52(m,1H),1.78(d,J=13.6Hz,6H); LC-MS(ESI)m / z:561.2[M+H] + .

[0169] Example 39: Preparation of 2-(4-(5-chloro-4-(2-dimethylphosphonophenyl)aminopyrimidin-2-ylamino)-3-methylpyrazole-2-methylpropionitrile

[0170] Refer to step 1 of Example 8 to obtain the target Example 39. 1 H NMR (400MHz, DMSO) δ11.24-11.11(m,1H),8.74-8.64(m,1H),8.51-8.31(m,1H),8.16-8.08(m,1H),8.01-7.87(m,1H),7.62-7. 52(m,1H),7.49-7.32(m,1H),7.17-7.05(m,1H),2.13(s,3H),1.89(s,6H),1.78(d,J=13.6Hz,6H); LC-MS(ESI)m / z:444.1[M+H] + .

[0171] Effect experiment:

[0172] Experimental Example 1: In vitro evaluation of the inhibitory activity of the test compound on LRRK2 and LRRK2(G2019S) kinases

[0173] Experimental purpose: To evaluate the inhibitory activity of the test compounds against LRRK2 and LRRK2(G2019S) kinases using Promega's ADP-Glo ​​Kinase Assay and calculate the IC50 value.

[0174] Materials and reagents: ADP-Glo ​​Kinase Assay (Promega, V9102); LRRK2 (Invitrogen, PV4873); LRRK2 (G2019S) (Carna, 09-146); LRRK2 tide (SignalChem, L10-58); ATP (Promega, V910B); DTT (SignalChem, D86-09B); DMSO (Sigma, D8418); GNE-0877 (MCE, HY-13488)

[0175] Experimental steps:

[0176] 1. Preparation of 1x kinase buffer: 1x kinase reaction buffer, 4x distilled water, and 1.5 mM DTT.

[0177] 2. Dissolve the positive control and test compound in DMSO to a 10 mM stock solution. Dilute each of these stock solutions to 100 μM with DMSO, then perform a 3-fold serial dilution to create 10 concentration gradients, starting at 100 μM. Negative controls for LRRK2 kinase and LRRK2(G2019S) kinase: 100% DMSO. Compound dilutions were transferred to each well of an assay plate (784075, Greiner) using an Echo 550 so that the concentrations of the test compounds and the positive control GNE-0877 in the final reaction solutions of the LRRK2 and LRRK2(G2019S) kinase assays were 1000 nM, 333.33 nM, 111.11 nM, 37.037 nM, 12.345 nM, 4.1152 nM, 1.3717 nM, 0.4572 nM, 0.1524 nM, and 0.0508 nM, respectively.

[0178] 3. Seal the assay plate and centrifuge the composite plate at 1000 g for 1 min.

[0179] 4. Prepare 2x enzyme in 1x kinase buffer: Prepare 2x LRRK2 and 2x LRRK2(G2019S) kinase solutions in 1x kinase reaction buffer.

[0180] 5. Add 2.5 μl of 2x enzyme to a 384-well assay plate (784075, Greiner), centrifuge the plate at 1000 g for 30 seconds, and incubate at room temperature for 10 minutes.

[0181] 6. Prepare a 2× substrate and ATP mix in 1× kinase buffer. Add 2.5 μl of the 2× substrate and ATP mix and centrifuge the plate at 1000 g for 30 seconds. Seal the plate and incubate at room temperature for 2 hours.

[0182] 7. Add 4 μl of ADP-Glo ​​reagent and incubate at room temperature for 40 minutes.

[0183] 8. Add 8 μl of kinase assay reagent and incubate at room temperature for 40 minutes.

[0184] 9. Read the luminescent signal on the Envision 2104 plate reader.

[0185] Calculation of inhibition percentage: Inhibition rate (%) = 100-(Signalcmpd-SignalAve PC) / (SignalAve VC-SignalAve PC)×100.

[0186] Calculate IC50 and fit compound dose-effect curves: GraphPad 8.0 was used to obtain the IC50 of the compound using the following nonlinear fitting formula:

[0187] Y=Bottom+(Top-Bottom) / (1+10^((LogIC50-X)*HillSlope))

[0188] Wherein, X: log value of compound concentration; Y: percentage of compound inhibition.

[0189] Quality Control: Z factor > 0.5; S / B > 2. Positive control IC50 is within 3 to 5 times the historical data.

[0190] Table 1: LRRK2 and LRRK2(G2019S) kinase inhibitory activity test results

[0191] Experimental Example 2

[0192] Experimental purpose: To evaluate the inhibitory ability of the test compound on the phosphorylation level of LRRK2 protein in Hek293 LRRK2 cells using AlphaLISA detection method.

[0193] Materials and reagents: Hek293-LRRK2 WT cells (stable cell line, Pharmaron), DMEM (Gibco), AlphaLISA SureFire Ultra p-LRRK2 (Ser935), Assay (PerkinElmer, ALSU-PLRRK2-A500), G418 (Gibco, 10131027), Penicillin-Streptomycin (Gibco, 15140-122), FBS (Gibco, 10099-141).

[0194] Experimental steps:

[0195] All cells were cultured according to ATCC recommendations. Cell exponential analysis was performed. Cell culture medium consisted of DMEM with 10% FBS and 1*PS, and 500 μg / ml G418. Culture conditions were 37°C, 95% air, and 5% carbon dioxide (CO2). Cells with a viability greater than 90% were harvested from flasks and 25 μl of the HEK293-LRRK2 cell suspension was dispensed into 384-well cell culture plates at a rate of 80,000 cells / well. Cells were incubated overnight at 37°C in a 5% CO2 incubator.

[0196] Test compounds were dissolved in DMSO to a 10 mM stock solution. All compounds were diluted 2-fold in DMSO and serially diluted 3-fold to create nine concentration gradients, including a compound-free DMSO sample, for a total of 10 stock concentrations. 25 nL of these serial dilutions were added to a 384-well cell plate using an echo plate and incubated in a 37°C, 5% CO2 incubator for 2 hours.

[0197] Detection: Cell lysates were prepared and assayed according to the manufacturer's protocol, and AlphaScreen values ​​were read using Envision.

[0198] Calculate the inhibition percentage: Inhibition rate (%) = 100-(Signalcmpd-SignalAve PC) / (SignalAve VC-SignalAve PC)×100

[0199] SignalAve PC: Average of AlphaScreen reads across the positive control wells

[0200] SignalAve VC: Average of AlphaScreen reads across the blank control wells

[0201] Calculation of IC50 and fitting of compound dose-effect curves: GraphPad 6.0 was used to obtain the IC50 of the compound using the following nonlinear fitting formula.

[0202] Y=Bottom+(Top-Bottom) / (1+10^((LogIC50-X)*HillSlope))

[0203] Wherein, X: log value of compound concentration; Y: percentage of compound inhibition.

[0204] Data Verification: Data were exported from the reader and analyzed manually. Luminescence values ​​were converted to % inhibition. All IC50s were first calculated using % inhibition using Prism Graphpad 5.0. Luminescence values ​​were then used to recalculate IC50s to verify the accuracy of the analysis.

[0205] Experimental results: The results of the LRRK2 protein phosphorylation inhibitory activity test in Hek293 LRRK2 cells are shown in Table 2.

[0206] Experimental Example 3

[0207] Experimental purpose: To evaluate the inhibitory ability of the test compound on the phosphorylation level of LRRK2 protein substrate Rab10 in LRRK2 R1441G mouse embryonic fibroblasts by Western Blot method.

[0208] 1. Cell line: (LRRK2R1441G mouse embryonic fibroblast, stable cell line)

[0209] 2. Dissolve the test compound in DMSO to a 10 mM stock solution. This stock solution was diluted 10-fold or 100-fold with DMSO, followed by a 2-fold or 10-fold serial dilution, resulting in four concentration gradients, as well as a compound-free DMSO sample, for a total of five stock solution concentrations.

[0210] 3. LRRK2 R1441G mouse embryonic fibroblasts were cultured using DMEM medium at 37°C and 5% (v / v) CO2, and the experiments were performed during the exponential growth phase.

[0211] 4. Gently discard the culture supernatant and wash the cells twice with PBS. Digest the cells with trypsin solution and terminate the digestion with complete culture medium. Collect the cells and count them. Seed the cells into 96-well cell culture plates at 5×10 cells per well. 4 cells, 100 μL of culture medium, and incubate the cell culture plate in a 37°C, 5% (v / v) CO2 incubator for 2 hours.

[0212] 5. Add 100 nL of the prepared compound working solution to each well of cells. The final concentrations of the test compound are: 100, 10, 1, 0.1 nM or 1000, 500, 100, 10 nM.

[0213] 6. Incubate the cell culture plate in a 37°C, 5% CO2 incubator for 1 hour.

[0214] 7. Protein Extraction and Sample Preparation: Discard the culture medium from the cell culture plate and add 45 μl of cell lysis working solution to each well. Incubate on ice for 30 minutes. Prepare the sample using 4x sample preparation solution and heat at 70°C for 10 minutes. Store the remaining protein sample at -80°C.

[0215] 8. Western Blot: Load 1-10 μg of sample per well on a precast gel and perform electrophoresis at a constant voltage of 120 V for approximately 60 minutes. Transfer to a PVDF membrane at a constant current of 300 mA for 1 hour. After transfer, block with blocking buffer for 1 hour at room temperature. Incubate with primary antibody working solution at 4°C overnight. Wash the membrane with 1× TBST buffer for 3×10 minutes. Incubate with secondary antibody working solution at room temperature for 1 hour. Wash the membrane with 1× TBST buffer for 3×10 minutes and develop color with a colorimetric solution.

[0216] 9. Data Analysis

[0217] Semi-quantitative analysis was performed by calculating the grayscale value of each band using ImagJ software. The grayscale values ​​of each p-Rab10 and Actin band were calculated using ImagJ software. The sample with 0 nM compound added was set to p-Rab10 / Actin% = 100%, and the relative values ​​of Rab10 / Actin% at other treatment concentrations were calculated.

[0218] GraphPad 8.0 was used to calculate the IC50 of the compounds using a nonlinear fitting formula.

[0219] Fitting formula: Y = Bottom + (Top - Bottom) / (1 + 10^((LogIC50 - X) * HillSlope))

[0220] Wherein, X: log value of compound concentration; Y: inhibition percentage of compound.

[0221] Experimental results: The test results of the compound inhibiting p-Rab10 activity in LRRK2 R1441G mouse embryonic fibroblasts are shown in Table 2.

[0222] Table 2: Test effects of compounds on inhibiting LRRK2 protein phosphorylation in Hek293 LRRK2 cells and p-Rab10 activity in LRRK2 R1441G mouse embryonic fibroblasts.

[0223] Note: “-” means not tested

[0224] The experimental results are shown in Tables 1 and 2, which confirm that the example compounds of the present invention effectively inhibit LRRK2, LRRK2 (G2019S) and Rab10 kinases. Therefore, the example compounds of the present invention can be effectively used in pharmaceutical compositions for treating and preventing diseases related to LRRK2, LRRK2 (G2019S) and Rab10 kinases.

[0225] Experimental Example 4: In vitro evaluation of the inhibitory activity of the test compound against EGFR T790M / C797S / L858R kinase

[0226] Experimental purpose: To evaluate the inhibitory activity of the test compounds against EGFR T790M / C797S / L858R kinase using Cisbio's HTRF KinEASE-TK kit and calculate the IC50 value.

[0227] Materials and reagents: HTRF KinEASE-TK kit (Cisbio); EGFR T790M / C797S / L858R (Signalchem); ATP (Promega, V910B); DTT (Invitrogen); DMSO (Sigma)

[0228] Experimental steps:

[0229] 1. Dissolve the positive control and test compound in DMSO to a 10 mM stock solution. Dilute each of the above stock solutions to 100 μM using DMSO, then perform a 3-fold gradient dilution to obtain 10 concentration gradients, with 100 μM as the starting concentration. Negative control: 100% DMSO. Transfer the diluted test compound working solution to each well of an Echo 550 reaction plate (784075, Greiner). The final concentrations of the test compound and positive control in the EGFR T790M / C797S / L858R kinase assay reaction solution are 1000 nM, 250 nM, 62.5 nM, 15.62 nM, 3.9 nM, 0.97 nM, 0.24 nM, and 0.06 nM, respectively.

[0230] 2. Seal the reaction plate with sealing film and centrifuge at 1000g for 1 minute.

[0231] 3. Prepare 2× kinase using 1× enzyme reaction buffer

[0232] 4. Add 5 μL of the above-prepared kinase solution to the reaction plate, seal the reaction plate with a sealing film, centrifuge at 1000 g for 30 seconds, and let it stand at room temperature for 10 minutes.

[0233] 5. Prepare a 2x kinase substrate and ATP mixture using 1x enzyme reaction buffer.

[0234] 6. Add 5 μL of the above solution to the reaction plate, centrifuge at 1000 g for 30 seconds, and start the reaction for 40 minutes.

[0235] 7. Add 5 μL of 4× Sa-XL 665-prepared HTRF detection buffer and 5 μL of TK-antibody-Cryptate to each reaction well, centrifuge at 1000 g for 30 seconds, and incubate at room temperature for 1 hour.

[0236] 8. Read the fluorescence signal values ​​at 615 nm (Cryptate) and 665 nm (XL665) on an Envision 2104 plate reader.

[0237] Calculation of inhibition percentage:

[0238] Inhibition rate (%)=100-(Ratiocmpd-RatioAve PC) / (RatioAve VC-RatioAve PC)×100.

[0239] Ration is the ratio of 665nM / 615nM readings in each test well

[0240] RatioAve PC: Average Ratio value of the entire positive control well

[0241] RatioAve_VC: Average Ratio value of the entire negative control well

[0242] Calculation of IC50 and fitting of compound dose-effect curves: GraphPad 6.0 was used to obtain the IC50 of the compound using the following nonlinear fitting formula:

[0243] Y=Bottom+(Top-Bottom) / (1+10^((LogIC50-X)*HillSlope))

[0244] Wherein, X: log value of compound concentration; Y: percentage of compound inhibition.

[0245] Quality control: Z factor>0.5; S / B>2, positive control IC50 is within 3 to 5 times the historical data.

[0246] Experimental results: The results of EGFR T790M / C797S / L858R kinase inhibitory activity test are shown in Table 3.

[0247] Experimental Example 5: In vitro evaluation of the inhibitory activity of the test compound on Ba / F3-FL EGFR Del19 / T790M / C797S cells

[0248] use The detection method evaluates the inhibitory ability of the test compound on the activity of Ba / F3-FL EGFR Del19 / T790M / C797S cells.

[0249] Materials and reagents: (Promega, G7573); RPMI-1640 (VivaCell, C3010-0500); Fetal bovine serum (VivaCell; C04001-500); Ba / F3-FL EGFR Del19 / T790M / C797S (Precedo, RPMI-1640+10%FBS+1%P / S)

[0250] Experiment and steps:

[0251] Preparation of working stock solutions of test compounds: Dissolve the test compound in DMSO to a 10 mM stock solution. Dilute the stock solution to 20 μM by adding 2 μL of the 10 mM stock solution to 98 μL of growth medium. Cell plating: Spin down the cells and resuspend them in growth medium. Count the cells using a cell counter. Dilute the cell suspension in growth medium to the desired density and plate 95 μL of the cell suspension into a 96-well plate.

[0252] Inhibition assay: Add 5 μL of 20 μM compound to a 96-well plate according to the plate map. The final DMSO concentration in each well is 0.1%. Incubate at 37°C, 5% CO2 for 72 hours.

[0253] Detection: Before detection, the assay plate was equilibrated to room temperature and 50 μL of CellTiter The mixture was shaken on an orbital shaker for 2 minutes to induce cell lysis, incubated at room temperature for 10 minutes to stabilize the luminescent signal, and the fluorescence value was recorded on a Paradigm.

[0254] Data analysis: Calculate the inhibition percentage according to the following formula:

[0255] Inhibition rate (%) = 100-(RLU compound-RLU blank) / ((RLU control-RLU blank)×100

[0256] Calculate IC50 and fit compound dose-effect curves

[0257] GraphPad 7.0 was used to obtain the IC50 of the compound using the following nonlinear fitting formula:

[0258] Y=Bottom+(Top-Bottom) / (1+10^((LogIC50-X)*HillSlope))

[0259] Experimental results: The inhibitory activity of Ba / F3-FL EGFR Del19 / T790M / C797S cells is shown in Table 3.

[0260] Table 3

[0261] Note: “-” means not tested

[0262] The experimental results are shown in Table 3, which confirm that the example compounds of the present invention effectively inhibit the activities of EGFR T790M / C797S / L858R and EGFR Del19 / T790M / C797S. Therefore, the example compounds of the present invention can be effectively used in pharmaceutical compositions for treating and preventing diseases associated with GFR T790M / C797S / L858R and EGFR Del19 / T790M / C797S.

[0263] Experimental Example 6 In vivo efficacy experiment

[0264] Experimental purpose: To evaluate the pharmacodynamics of the compound on LRRK2 levels in CD-1 mice and provide a reference for clinical research.

[0265] Experimental materials: CD-1 mice (6-8 weeks old, male, 25.6-29.5 g); experimental animal provider: Beijing Sibeifu Biotechnology Co., Ltd.

[0266] Experimental process:

[0267] 1. Animal husbandry, grouping and handling

[0268] 1.1 Quarantine

[0269] The quarantine period was 7 days, routine health examinations were performed by a veterinarian, and animals with abnormal performance were culled before the experiment.

[0270] 1.2 Animal housing conditions

[0271] Experimental animals were housed in an SPF-rated, laminar flow cleanroom with a constant temperature and humidity, with three mice per cage. The room temperature was maintained at 22 ± 3°C, the humidity was 40-80%, and the lighting was alternating between 12 hours of light and dark. The cages were made of polycarbonate. The bedding used was autoclaved soft corncob and was changed twice weekly. The drinking water was autoclaved, and the food was irradiated with cobalt-60 radiation. The animals had free access to sterile food and water.

[0272] 1.3 Animal number

[0273] Each cage was labeled with the number of animals, sex, strain, date of receipt, group, and start time of the experiment. Each animal was individually numbered on its tail.

[0274] 1.4 Animal grouping and treatment

[0275] On the day of administration, the animals were randomly divided into 6 groups according to their body weight, with 3 animals in each group. The specific grouping and administration schedule are shown in Table 4.

[0276] Table 4 Animal grouping and drug administration

[0277] Note: Solvent (ethanol:0.5% methylcellulose (1:19)).

[0278] 2. Medication, Blood Collection, and Tissue Collection

[0279] The vehicle or test compound was administered sequentially. Five hours after administration, the mice were killed by carbon dioxide anesthesia, and blood was collected by cardiac puncture in EP tubes containing EDTA-K2. The blood samples were immediately centrifuged at 2000 g for 5 minutes at 4°C. The supernatant was collected and transferred to a new EP tube, and the plasma was stored at -80°C for Western blot analysis (LRRK2, LRRK2-pS935).

[0280] After blood collection, the brains of all animals were collected by dissection, frozen on dry ice, and stored in a -80°C refrigerator for Western blot analysis (LRRK2, LRRK2-pS935).

[0281] 3. Experimental methods and steps

[0282] 3.1 Buffer preparation:

[0283] 3.1.1RIPA Lysis Buffer:

[0284] 50 mL of RIPA lysis buffer contains the following components:

[0285] Complete ultra TabletsMini.EDTA-free, easypack and phosphatase inhibitor cocktail.

[0286] Keep the prepared lysis buffer on ice until use;

[0287] 3.1 2 Transfer Buffer:

[0288] Add and dissolve 100 mL of 10× transfer buffer and 200 mL of methanol in 700 mL of ddH2O.

[0289] 3.1.3 MOPS electrophoresis buffer:

[0290] 100 mL of 20× MOPS buffer was diluted to 2000 mL with ddH2O.

[0291] 3.1.4 TBST buffer:

[0292] Dilute 100 mL of 10× TBST buffer to 1000 mL with ddH2O.

[0293] 3.1.5 Blocking buffer:

[0294] 2.5 g of skim milk was dissolved in 50 mL of 1× TBST buffer and stored at 4°C.

[0295] 3.1.6 Primary antibody solution:

[0296] Dilute the target primary antibody at a ratio of 1:1000 in blocking buffer and dilute the internal control antibody at a ratio of 1:5000 in blocking buffer.

[0297] 3.1.7 Secondary antibody solution:

[0298] The secondary antibody was diluted in antibody solution at a ratio of 1:5000.

[0299] 3.2. Protein lysate preparation

[0300] 3.2.1 Resuspend the sample (approximately 30 mg) in 300 μL of lysis buffer and homogenize the sample using a TissueLyser II at 30 Hz for 3 minutes using grinding beads in a refrigerator. Place the tube on ice and mix the sample at 4°C for 30 minutes.

[0301] 3.2.2 Centrifuge at 12,000 g for 15 minutes at 4°C to pellet any remaining undissolved tissue. Collect the supernatant into clean Eppendorf centrifuge tubes, aliquot the supernatant into small volumes, and store at -80°C.

[0302] 3.2.3 Determine the protein concentration of 3 μg / μl using BCA assay.

[0303] 3.3 Immunoblotting

[0304] 3.3.1 Extract 30 μg of protein from each sample and run electrophoresis at a constant voltage of 120 V until the blue marker reaches the end of the gel.

[0305] 3.3.2 Transfer to NC membrane using Transblot (0.3A, 1.5h).

[0306] 3.3.3 After transfer, block the membrane with blocking buffer at room temperature for 1 hour.

[0307] 3.3.4 Incubate the membrane with the primary antibody at the recommended dilution using Antibody Dilution Buffer at 4°C overnight.

[0308] 3.3.5 Wash the membrane with 1× TBST for 6 x 5 min and incubate the membrane with secondary antibody for 1 hour at room temperature.

[0309] 3.3.6 Wash the membrane with 1× TBST for 6×5 min and detect with Odyssey CLx.

[0310] 3.3.7 Use Image Studio to analyze the ratio of the target band.

[0311] 4. Experimental results:

[0312] 4.1 The results of brain tissue immunoblotting (Western Blot) are shown in Figure 4.

[0313] 4.2 The results of plasma immunoblotting (Western Blot) are shown in Figure 5.

[0314] Conclusion: The compound of the present invention has a significant inhibitory effect on the phosphorylation level of LRRK2 in mouse brain tissue.

[0315] Experimental Example 7 In vivo efficacy in tumor models

[0316] Objective: To evaluate the efficacy of the compound in a human ovarian cancer model

[0317] 1. Female BALB / c nude mice, 5-6 weeks old.

[0318] Day 2: All animals were subcutaneously inoculated with OVCAR8 cells; the average tumor volume reached 150-200 mm 3 The medication was divided into groups as shown in Table 5.

[0319] Table 5

[0320] The animals were observed at the cage side once a day and observed in detail after each drug administration. After the start of drug administration, the body weight and tumor volume were measured twice a week. On the day of the end of the experiment, the animals were photographed by group, the weight of the exfoliated tumor was weighed, and the whole exfoliated tumor was photographed by group.

[0321] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention and are not intended to limit the scope of protection of the present invention. Although the present invention has been described in detail with reference to preferred embodiments, those skilled in the art should understand that the technical solutions of the present invention may be modified or replaced by equivalents without departing from the essence and scope of the technical solutions of the present invention.

Claims

1. A heteroaryl derivative, characterized in that: The general structural formula I is as follows: in: X and Y are independently selected from halogen or hydrogen, or together with the nitrogen-containing six-membered ring to which they are connected, form a nitrogen-containing five-membered ring; R1 is a 5-6 membered aromatic group or a heteroaromatic group containing N and S, the aromatic ring and the heteroaromatic group are substituted by 0-2 substituents, the substituents are C1-3 alkyl groups or alkyl groups substituted by cyano groups; or two substituents can be connected to form a ring, the ring is a 5-7 membered cycloalkyl group, a lactam cycloalkyl group or a heterocycloalkyl group or heteroaromatic group containing N and O, the heterocycloalkyl group or heteroaromatic group is substituted by 0-3 substituents, the substituents are C1-3 alkyl groups, keto groups, trifluoroacetyl groups, hydroxyacetyl groups, alkylamino groups, heterocycloalkanoyl groups.

2. The heteroaryl derivative according to claim 1, characterized in that: Y is selected from Cl, X is selected from H, or the nitrogen-containing six-membered ring they are connected to together form 3. The heteroaryl derivative according to claim 1, characterized in that: R1 is One of them.

4. The heteroaryl derivative according to claim 1, characterized in that: The compound of general formula I is one of the following: Preparation of (2-((5-chloro-2-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide; (2-(2-(1-methyl-1H-pyrazol-4-yl)amino)-7H-purin-6-yl)amino)phenyl)dimethylphosphine oxide; (2-(2-(1-methyl-1H-pyrazol-3-yl)amino)-7H-purin-6-yl)amino)phenyl)dimethylphosphine oxide; (2-(2-((1H-indazol-6-yl)amino)-7H-purin-6-amino)phenyl)dimethylphosphine oxide; (2-((5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)amino)-7H-purin-6-yl)amino)phenyl)dimethylphosphine oxide; 1-(2-((6-((2-(dimethylphosphoryl)phenyl)amino)-7H-purin-2-yl)amino)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)-2,2,2-trifluoroethanone; 1-(2-((6-((2-(dimethylphosphoryl)phenyl)amino)-7H-purin-2-yl)amino)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)-2-hydroxyethan-1-one (2-((2-((5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)amino)-7H-purin-6-yl)amino)phenyl)dimethylphosphine oxide; 6-((6-((2-(dimethylphosphoryl)phenyl)amino)-7H-purin-2-yl)amino)-3,4-dihydroquinolin-2(1H)-one; (2-((2-(1,2,3,4-tetrahydroquinolin-6-yl)amino)-7H-purin-6-yl)amino)phenyl)dimethylphosphine oxide; 7-((6-((2-(dimethylphosphoryl)phenyl)amino)-7H-purin-2-yl)amino)-3,4-dihydroquinolin-2(1H)-one; (2-((2-(1,2,3,4-tetrahydroquinolin-7-yl)amino)-7H-purin-6-yl)amino)phenyl)dimethylphosphine oxide; 2-(4-((6-((2-(dimethylphosphoryl)phenyl)amino)-7H-purin-2-yl)amino)-3-methyl-1H-pyrazol-1-yl)-2-methylpropionitrile; (2-((6-(((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide; (2-((6-(((5-methyl-4,5,6,7-tetrahydrothiazol[5,4-c]pyridin-2-yl)amino)-1H-pyrazol[3,4-d]pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide; (2-((6-((6-propylamino)-4,5,6,7-tetrahydrobenzo[d]thiazol-2-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide; 1-(2-((4-((2-(dimethylphosphoryl)phenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-6-yl)amino)-7,8-dihydro-1,6-naphthyridin-6(5H)yl)-2,2,2-trifluoroethanone; (2-((6-((5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide; 1-(3-((4-((2-(dimethylphosphoryl)phenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-6-yl)amino)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)-2-hydroxyethan-1-one; (2-((2-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide; (2-((2-((5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)amino)-7Hpyrrolo[2,3-d]pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide; 1-(2-((4-((2-(dimethylphosphoryl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)-2-hydroxyethan-1-one; 1-(2-((4-((2-(dimethylphosphoryl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)-2-2,2,2-trifluoroethanone; (2-((5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide; 2-(4-((4-)((2-(dimethylphosphoryl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methyl-1H-pyrazol-1-yl)-2-methylpropionitrile; 6-((4-((2-(dimethylphosphoryl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3,4-dihydroquinolin-2(1H)-one; (2-(((1,2,3,4-tetrahydroquinolin-6-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)aminophenyl)dimethylphosphine oxide; 7-((4-((2-(dimethylphosphoryl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3,4-dihydroquinolin-2(H)-one; (2-(((1,2,3,4-tetrahydroquinolin-7-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)aminophenyl)dimethylphosphine oxide; 1-(2-((4-((2-(dimethylphosphoryl)phenyl)amino)-5H-pyrrolo[3,2-d]pyrimidin-2-yl)amino)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)-2-hydroxyethan-1-one; 2-(2-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)amino)-5H-pyrrolo[3,2-d]pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide; (2-((5-chloro-2-((6-(propylamino)-4,5,6,7-tetrahydrobenzothiazol-2-yl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide; 1-(2-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)-2,2,2-trifluoroethanone; (2-(5-chloro-2-((5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)amino)pyrimidin-4-yl)amine)phenyldimethylphosphine oxide; (2-((5-chloro-2-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide; 1-(2-(5-chloro-4-(2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)-2-hydroxyethan-1-one; (2-((5-chloro-2-((6-methyl-5,6,7,8-tetrahydro-4H-thiazolo[4,5-d]azepin-2-yl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide; 2-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-7,8-dihydro-4H-thiazolo[4,5-d]azepin-6(5H)-yl)(tetrahydro-2H-pyran-4-yl)methanone; 2-(4-(5-Chloro-4-(2-dimethylphosphonophenyl)aminopyrimidin-2-ylamino)-3-methylpyrazole-2-methylpropionitrile.

5. Use of the heteroaryl derivative according to any one of claims 1 to 3 in the preparation of LRRK2 kinase or abnormal LRRK2 mutant kinase and / or EGFR mutant kinase inhibitor drugs.

6. A drug for inhibitor of LRRK2 kinase or / and abnormal LRRK2 mutant kinase or / and EGFR mutant kinase, characterized in that: A heteroaryl derivative comprising any one of claims 1 to 3 or an enantiomer, diastereomer, tautomer, solvate, polymorph, hydrate, deuterated analog, prodrug, pharmaceutically acceptable salt or excipient or excipient thereof.

7. A pharmaceutical composition, characterized in that: The invention comprises a heteroaryl derivative according to any one of claims 1 to 3 or an enantiomer, diastereomer, tautomer, solvate, polymorph, hydrate, deuterated analog, prodrug, pharmaceutically acceptable salt or excipient thereof.

8. A pharmaceutical composition, characterized in that: The pharmaceutical composition is a combination of the drug described in claim 7 and other drugs, and the other drugs are drugs for treating breast cancer.

9. The LRRK2 kinase or / and abnormal LRRK2 mutant kinase or / and EGFR mutant kinase inhibitor drug according to claim 6 or the pharmaceutical composition according to claim 7 or 8, characterized in that: The dosage form is tablet, capsule, solution, suspension, granule or injection, and is administered orally or parenterally.

10. Use of the heteroaryl derivative according to any one of claims 1 to 3, or the LRRK2 kinase or abnormal LRRK2 mutant kinase or / and EGFR mutant kinase inhibitor according to claim 6, or the pharmaceutical composition according to claim 7 or 8 in the preparation of drugs for preventing and / or treating central nervous system diseases, cancer and immune diseases.

11. The use according to claim 10, characterized in that: The central nervous system (CNS) diseases include Alzheimer's disease, L-dopa-induced dyskinesia, Parkinson's disease, ischemic stroke, traumatic brain injury or spinal cord injury; the cancers include kidney cancer, breast cancer, prostate cancer, blood cancer, papilloma, lung cancer, acute myeloid leukemia, multiple myeloma, brain cancer, etc.; the immune diseases include leprosy, Crohn's disease, inflammatory bowel disease, ulcerative colitis, amyotrophic lateral sclerosis, rheumatoid arthritis or ankylosing spondylitis.

Citation Information

Patent Citations

  • Phosphorous derivatives as kinase inhibitors

    CN102105150A

  • Pyrimidopyrazole compounds as fourth generation EGFR inhibitors

    CN112771032A

  • Pyrrolopyrimidine derivative as well as preparation method and application thereof

    CN113087709A

  • Selective EGFR inhibitor

    CN113896744A

  • Novel pyrimidine derivative and use thereof

    CN114829344A